Breaking Barriers: Ovarian Cancer Study Expanded to Africa

By Stacy M. Brown | NNPA(NNPA) – Sylvester Comprehensive Cancer Center researchers Dr. Sophia George and Dr. Matthew Schlumbrecht are leading an ambitious study focused on ovarian cancer treatment for women of African descent. Their work, based at the University of Miami Miller School of Medicine, aims to address a critical gap in cancer research: the underrepresentation of Black women in clinical trials, specifically for the drug niraparib.George, a molecular geneticist, and Schlumbrecht, a gynecologic oncologist, have expanded their research beyond the U.S. and the Caribbean to Africa. In July, they launched the study in Nigeria, giving them access to data from a population often overlooked in cancer research. According to the University of Miami, their goal is to understand how women of African ancestry metabolize drugs like niraparib, a PARP inhibitor that has transformed treatment for certain ovarian cancer patients.While niraparib has proven effective, Black women made up only 1.6% of participants in the drug’s pivotal PRIMA study. George and Schlumbrecht’s new study is specifically designed to address this gap by enrolling women of African descent.“We know from other drugs that how women of African ancestry metabolize drugs can differ from those of European ancestry,” Dr. Schlumbrecht explained in...